PLUS1
2.69
-0.12 (-4.27%)
-0.12 (-4.27%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ADiTx Therapeutics Inc | ADTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.12 | -4.27% | 2.69 | 18:14:51 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.00 | 2.26 | 3.00 | 2.54 | 2.81 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 2.55 | 2.65 | 0.10 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,607 | 767,681 | $ 2.57 | $ 1,974,249 | 6,249,812 | 1.62 - 10.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:14:50 | 20 | $ 2.65 | USD |
ADiTx Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 33.03M | 12.28M | 10.46M | $ - | $ - | -1.05 | -5.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 12.70% |
ADiTx Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/04/2021 | 08:30 | GlobeNewswire Inc. | Eazy Testing Inc. Becomes AditxtScore⢠Channel Partner, to.. |
| 3/01/2021 | 06:40 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 3/01/2021 | 06:32 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/26/2021 | 17:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/12/2021 | 16:08 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) |
| 2/11/2021 | 16:01 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) |
| 2/11/2021 | 13:15 | Seeking Alpha | ESSA Pharma leads healthcare gainers; Pulmatrix, Aphria.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.07 | 3.27 | 2.26 | 3.04 | 534,079 | -0.38 | -12.38% |
| 1 Month | 3.72 | 5.59 | 2.26 | 4.45 | 1,879,787 | -1.03 | -27.69% |
| 3 Months | 2.40 | 6.73 | 1.96 | 3.65 | 4,190,354 | 0.29 | 12.08% |
| 6 Months | 2.24 | 6.73 | 1.62 | 3.31 | 2,430,192 | 0.45 | 20.09% |
| 1 Year | 5.28 | 10.40 | 1.62 | 4.26 | 2,385,664 | -2.59 | -49.05% |
| 3 Years | 5.28 | 10.40 | 1.62 | 4.26 | 2,385,664 | -2.59 | -49.05% |
| 5 Years | 5.28 | 10.40 | 1.62 | 4.26 | 2,385,664 | -2.59 | -49.05% |
ADiTx Therapeutics Description
| ADiTx Therapeutics Inc is a pre-clinical stage, life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |
